Production & Sales

Rosemont Pharmaceuticals acquires Lucis Pharma

Rosemont Pharmaceuticals has acquired Lucis Pharma, which is a specialist pharmaceutical business in the UK, for undisclosed amount.

Alvotech partners with Advanz for biosimilars commercialisation in Europe

Alvotech and Advanz Pharma have extended their strategic partnership for the supply and commercialisation of five biosimilars in Europe.

Navamedic announces $7.2m cash offer for Sensidose acquisition

Nordic pharma company Navamedic ASA has offered $7.2m (SEK75m) to purchase all shares in Sweden-based pharmaceutical firm Sensidose AB.

OncoVent signs agreement with Orient EuroPharma for oregovomab

Shenzhen Hepalink Pharmaceutical Group’s subsidiary OncoVent has entered into a licence and distribution agreement with Orient EuroPharma (OEP) for the immunotherapeutic drug candidate, oregovomab.

Pfizer to deliver 2.5 million additional doses of Covid-19 pill to UK

Pfizer has signed an agreement to deliver an additional 2.5 million treatment courses of its investigational Covid-19 pill Paxlovid to the UK.

Prestige BioPharma and Dr. Reddy’s partner to sell trastuzumab biosimilar

Prestige BioPharma and Dr. Reddy’s Laboratories have signed a binding agreement to commercialise the former’s trastuzumab (HD201) biosimilar in select Latin America and Southeast Asian countries.

Adaptimmune and Genentech partner on allogeneic cell therapies

Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, for the development and commercialisation of allogeneic cell therapies across several cancer indications.

STADA to acquire Sanofi’s consumer healthcare brands

German generic drug manufacturer STADA Group has agreed to acquire a portfolio of well-established consumer healthcare brands from biopharmaceutical firm Sanofi to expand its European Consumer Healthcare portfolio.

Danaher to acquire Aldevron from EQT for $9.6bn

Danaher, a science and technology company, has agreed to acquire biotech firm Aldevron from EQT Private Equity for an enterprise value of $9.bn.